ProSomnus Announces Third Quarter 2023 Investor Call and Business Update
October 31 2023 - 4:05PM
ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative
for the treatment of Obstructive Sleep Apnea (“OSA”), will report
its third quarter financial results after market close
on Thursday, November 9, 2023. ProSomnus Chief Executive
Officer, Len Liptak, and Chief Financial Officer, Brian
Dow, will host a conference call at 1:30 pm
PT / 4:30 pm ET.
Investor Call Dial-In InformationInterested
parties may register for the conference call using the following
link: ProSomnus Q3 2023 Conference Call. You may access the live
webcast of the conference call by using the following link:
ProSomnus Q3 2023 Webcast. The link will also be posted in the
Investor Relations section of the ProSomnus website at News
& Events.
About ProSomnusProSomnus (NASDAQ: OSA) is
a leading CPAP alternative for the treatment of Obstructive Sleep
Apnea, a serious medical disease affecting over 1 billion people
worldwide, that is associated with comorbidities including heart
failure, stroke, hypertension, morbid obesity, and type 2 diabetes.
ProSomnus intraoral medical devices are engineered to precisely
track the treatment plan and anatomy for each patient.
Non-invasive, patient preferred and easy to use, ProSomnus devices
have demonstrated excellent efficacy, safety, adherence, and
overall outcomes in a growing body of clinical investigations.
ProSomnus precision intraoral devices are FDA-cleared, patented,
and covered by commercial medical insurance, Medicare, TRICARE and
many Government sponsored healthcare plans around the world,
representing over 200 million covered lives. To learn more,
visit www.ProSomnus.com.
Investor ContactMike CavanaughICR
WestwickePhone:
+1.617.877.9641Email: Mike.Cavanaugh@westwicke.com
Media ContactElizabeth ColemanICR
WestwickePhone:
+1.203.682.4783Email: Elizabeth.Coleman@westwicke.com
ProSomnus (NASDAQ:OSA)
Historical Stock Chart
From Jul 2024 to Aug 2024
ProSomnus (NASDAQ:OSA)
Historical Stock Chart
From Aug 2023 to Aug 2024